Asset profile
BMS-986326
Biologic — subtype unspecified
Evidence outlook · lead readout
NCT06248814 · Dermatitis, Atopic
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06248814: This was a real randomized, double-blind, placebo-controlled crossover trial, but its primary endpoints were safety measures (adverse events, lab and vital-sign abnormalities) rather than a measure of skin improvement, and results have not yet been reported.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.